Identification of novel Kv1.3 blockers using a fluorescent cell-based ion channel assay

Journal of Biomolecular Screening

Volumn 11, Issue 1, 2006, Pages 57-64

  Slack, Mark ^a   Kirchhoff, Christian ^a   Smoller, Clemen ^a   Winkler, Dirk ^a   Netzer, Rainer ^a  

^a EVOTEC AG   (Germany)

Author keywords

Blocker; Diabetes; Ion channel; Kv1.3; T lymphocytes

Indexed keywords

POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHANNEL HERG; POTASSIUM CHANNEL KV1.3; POTASSIUM CHANNEL KV1.3 BLOCKING AGENT; UNCLASSIFIED DRUG; VOLTAGE GATED POTASSIUM CHANNEL;

ANIMAL CELL; ARTICLE; CELL ASSAY; CELL LINE; CONTROLLED STUDY; DATA ANALYSIS; DOSE RESPONSE; DRUG POTENCY; DRUG SELECTIVITY; DRUG TARGETING; ELECTROPHYSIOLOGY; FEMALE; FLUORESCENT CELL BASED ION CHANNEL ASSAY; FOLLOW UP; HIGH THROUGHPUT SCREENING; IC 50; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

ANIMALS; BIOLOGICAL ASSAY; CELLS; CHO CELLS; CRICETINAE; CRICETULUS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; ELECTROPHYSIOLOGY; FLUORESCENCE; KV1.3 POTASSIUM CHANNEL; POTASSIUM CHANNEL BLOCKERS; REPRODUCIBILITY OF RESULTS; STATISTICS; STATISTICS AS TOPIC; STRUCTURE-ACTIVITY RELATIONSHIP;

ANIMALIA;

EID: 32844461535     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057105282712     Document Type: Article

References (27)

1. Jentsch TJ, Huebner CA, Fuhrmann JC: Ion channels: Function unravelled by dysfunction. Nat Cell Biol 2004 ; 6: 1039-1047.
2. Ackermann MJ, Clapham DE: Ion channels: basic science and clinical disease. New Engl J Med 1997 ; 336: 1575-1586.
3. Coghlan MJ, Carroll WA, Gopalakrishan M: Recent Developments in the biology and medicinal chemistry of potassium channel modulators: update from a decade of progress. J Med Chem 2001 ; 44: 1627-1653.
4. Anger T, Madge DJ, Mulla M, Riddall D: Medicinal chemistry of neuronal voltage-gated sodium channel blockers. J Med Chem 2001 ; 44: 115-137.
5. Philipson LH, Hice RE, Schaefer K, LaMendola J, Bell GI, Nelson DJ,, et al. Sequence and functional expression in Xenopus ooyctes of a human insulinoma and islet potassiumchannel. Proc Natl Acad Sci USA 1991 ; 88: 53-57.
6. Attali B, Romey G, Honore E, Schmid-Alliana A, Mattei MG, Lesage F,, et al. Cloning, functional expression, and regulation of two K+ channels in human T lymphocytes. J Biol Chem 1992 ; 267: 8650-8657.
7. Szabo I, Bock J, Jekle A, Soddemann M, Adams C, Lang F,, et al. Anovel potassium channel in lymphocyte mitochondria. J Biol Chem 2005 ; 280: 12790-12798.
8. Beeton C, Pennington MW, Wulff H, Singh S, Nugent D, Crossley G,, et al. Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases. Mol Pharmacol 2005 ; 67: 1391-1381.
9. Koo GC, Blake JT, Talento A, Nguyen M, Lin S, Sirotina A,, et al. Blockade of the voltage-gated potassium channel Kv1.3 inhibits immune responses in vivo. J Immuno 1997 ; 158: 5120-5128.
10. Xu J, Wang P, Li G, Li G, Kaczmarek LK, Wu Y,, et al. The voltage-gated potassiumchannel Kv1.3 regulates peripheral insulin sensitivity. Proc Natl Acad Sci USA 2004 ; 101: 3112-3117.
11. Felix JP, Bugianesi RM, Schmalhofer WA, Borris R, Goetz MA, Hensens OD,, et al. Identification and biochemical characterization of a novel nortriterpene inhibitor of the human lymphocyte voltage-gated potassium channel Kv1.3. Biochemistry 1999 ; 38: 4922-4930.
12. Hill RJ, Grant AM, Volberg W, Rapp L, Faltynek C, Miller D,, et al. WIN 17317-3: novel nonpeptide antagonist of voltage activated K+ channels in human T lymphocytes. Mol Pharmacol 1995 ; 48: 98-104.
13. Hanson DC, Nguyen A, Mather RJ, Rauer H, Koch K, Burgess LE,, et al. UK-78,282, a novel piperidine compound that potently blocks the Kv1.3 voltagegated potassium channel and inhibits human T-cell activation. Br J Pharmacol 1999 ; 126: 1707-1716.
14. Schmalhofer WA, Bao J, McManus OB, Green B, Matyskieda M, Wunderler D,, et al. Identification of a new class of inhibitors of the voltage-gated potassium channel Kv1.3 with immunosuppressant properties. Biochemistry 2002 ; 41: 7781-7794.
15. Vennekamp J, Wulff H, Beeton C, Calabresi PA, Grissmer S, Hansel W,, et al. Kv1.3-blocking 5-phenylalkoyxpsoralens: a new class of immunomodulators. Mol Pharmacol 2004 ; 65: 1364-1374.
16. Baell JB, Gable RW, Harvey AJ, Toovey N, Herzog T, Hansel W,, et al. Khellinone derivatives as blockers of the voltage-gated potassium channel Kv1.3: synthesis and immunosuppressive activity. J Med Chem 2004 ; 47: 2326-2336.
17. Zheng W, Spencer RH, Kiss L: High throughput assay technologies for ion channel drug discovery. Assay Drug Dev Technol 2004 ; 2: 543-552.
18. Xu J, Wang X, Ensign B, Li M, Wu L, Guia A,, et al. Ion-channel assay technologies: quo vadis? Drug Disc Today 2001 ; 6: 1278-1241.
19. Wolff C, Fuks B, Chatelain P: Comparative study of membrane potentialsensitive fluorescent probes and their use in ion channel screening assays. J Biomol Screen 2003 ; 8: 533-543.
20. Zhang S, Kehl SJ, Fedida D: Modulation of human ether-a-go-go related K+(HERG) channel inactivation by Cs+ and K+. JPhysiol 2003 ; 548: 691-702.
21. Hamill OP, Marty A, Neher E, Sakmann B, Sigworth FJ: Improved patchclamp techniques for high-resolution current recording from cells and cellfree membrane patches. PFlugers Arch 1981 ; 391: 85-100.
22. "UNITY." St. Louis, MO: Tripos, 2002.
23. Sammon JW: A nonlinear mapping for data structure analysis. IEEE Trans Comput 1969 ; C-18: 401-409.
24. Zhang JH, Chung TD, Oldenburg KR: A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 1999 ; 4: 67-73.
25. Leonard RJ, Garcia ML, Slaughter RS, Reuben JP: Selective blockers of voltage-gated K+ channels depolarize human T lymphocytes: mechanism of the antiproliferative effect of charybdotoxin. Proc Natl Acad Sci USA 1992 ; 89: 10094-10098.
26. Wulff H, Beeton C, Chandy KG: Potassium channels as therapeutic targets for autoimmune disorders. Curr Opin Drug Disc Develop 2003 ; 6: 640-647.
27. Roden DM: Drug-induced prolongation of the QT interval. N Engl J Med 2004 ; 350: 1013-1022.